Mainstay Medical Holdings plc announces the limited commercial launch in the US of ReActiv8, its implantable Restorative Neurostimulation system to treat intractable chronic low back pain.
The ReActiv8 system will be available in the US through ReActiv8-certified physicians commencing in the summer of 2021, according to a news release.
“We are delighted to commercially launch ReActiv8 in the US and make this innovative Restorative Neurostimulation therapy available to Americans suffering from intractable chronic low back pain. Physicians will finally have access to a therapy to treat these patients beyond temporary treatments designed to merely mask the pain for a limited time. We are launching in a limited fashion to ensure we provide proper education to physicians and assist them in selecting the appropriate patients.”
— Jason Hannon, CEO of Mainstay Medical
New Website, Updates
To support the US commercial launch, Mainstay Medical has launched a new corporate website centered around patient and physician education.
In addition to the new website, the Company has introduced updated tools, guidance, and training materials to assist in identifying prospective patients for ReActiv8 therapy, educating physicians on the ReActiv8 system and becoming ReActiv8-certified, and helping patients access ReActiv8 in the US.
Specific resources include physician training protocols and modules on ReActiv8, educational and marketing collateral, and informative videos that support and further physician education, patient identification, and appropriate product use, the release continues.
“We are equipping ReActiv8-certified physicians with robust tools and information to enable proper patient identification and education. We expect that these resources will facilitate the identification of strong candidates for ReActiv8 and drive compelling patient outcomes,” Hannon adds.
[Source(s): Mainstay Medical Business Wire]
NeuroSphere myPath App Tracks and Reports Pain Relief
FDA Approves Abbott’s Smartphone-Compatible Digital Health Tool
Quell Technology to be Used in NIH-Funded Trial Evaluating TENS for Fibromyalgia